BusinessSummit Announces Positive Top-Line Data From an Exploratory Phase 2 Clinical Trial Supporting Ridinilazole as a Highly Selective Antibiotic for the Treatment of CDIBy Nasdaq OMXSep 5, 2017, 11:01 AM UTC
